Open AccessSAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
Author(s) -
Awadhesh Kumar Singh,
Ritu Singh
Publication year - 2019
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_12_19
Subject(s) - saxagliptin , medicine , empagliflozin , liraglutide , semaglutide , alogliptin , dulaglutide , exenatide , canagliflozin , sitagliptin , dapagliflozin , pharmacology , type 2 diabetes , lixisenatide , diabetes mellitus , endocrinology
Since 2008 United State (US) food drug administration mandate, several newer anti-diabetic drugs (ADD) have undergone a mandatory cardiovascular (CV) outcome trial (CVOT) in type diabetes (T2DM) patients with high CV risk. These includes CVOT done with dipeptidyl-peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonist (GLP-1RAs). Several double-blind, randomized, placebo-controlled CVOT have been presented and published in the last decade (2008-2018).